(NASDAQ: AKYA) Akoya Biosciences's forecast annual revenue growth rate of 12.08% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.7%.
Akoya Biosciences's revenue in 2025 is $81,672,000.On average, 3 Wall Street analysts forecast AKYA's revenue for 2025 to be $4,554,360,806, with the lowest AKYA revenue forecast at $4,448,600,680, and the highest AKYA revenue forecast at $4,675,763,268. On average, 3 Wall Street analysts forecast AKYA's revenue for 2026 to be $5,280,234,944, with the lowest AKYA revenue forecast at $4,946,764,250, and the highest AKYA revenue forecast at $5,560,003,605.
In 2027, AKYA is forecast to generate $5,330,350,199 in revenue, with the lowest revenue forecast at $5,330,350,199 and the highest revenue forecast at $5,330,350,199.